Sandoz stock: CEO outlines Bio100 growth plan
Published on 11/18/2026 at 18:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSGrowth plan and execution
- Sandoz said biosimilar sales grew 17 percent in the latest quarter.
- Management targets a 30 to 35 percent global biosimilar market share by 2035.
- The company plans to source at least 60 percent of manufacturing volume from its own network by 2035.
Sandoz outlined the next phase of its Bio100 strategy at the Jefferies Global Healthcare Conference on Wednesday, November 18, 2026. In a transcript published by Investing.com, Chief Executive Richard Saynor described biosimilars, generics and tighter supply-chain control as the core of the company's long-term plan.
Saynor said Sandoz's biosimilar business grew 17 percent in the latest quarter. Management wants to lift its global biosimilar market share from about 20 percent to 30 to 35 percent by 2035, while the company is targeting annual EBITDA margin improvement of about one percentage point and a margin of about 30 percent by that year.
Launches support the next phase
The CEO pointed to several growth drivers from 2027 onward. These include insulin biosimilars in Europe, four planned biosimilar launches in Japan and the US aflibercept opportunity associated with Enzeevu. Saynor said the aflibercept private-label arrangement is expected to begin contributing in the second half of 2027, with value carrying into 2028.
Sandoz launched Enzeevu in the United States on November 16, alongside a multi-year private-label agreement. The company will manufacture the aflibercept biosimilar for private-label commercialization, with committed volumes starting in the second half of 2027. The conference remarks added management's view that the agreement is a profitable and attractive way to enter the market, while not representing a broad strategic shift toward own-label products.
Supply control remains central
Sandoz is expanding its manufacturing base as it seeks greater control over costs and supply. Saynor said the Slovenia facility has 120,000 liters of large fed-batch capacity and can be expanded. The company aims to source at least 60 percent of its manufacturing volume from its own vertically integrated network by 2035.
The strategy offers investors a mix of product launches and operational execution. It also carries pricing and implementation risks, which management linked to competition, regulatory progress and the ability to bring additional capacity online. Sandoz stock traded at 88.11 euros on Lang & Schwarz at 18:01 CET on Wednesday, November 18, 2026.
Sandoz Group AG
- ISIN: CH1243598427
- Ticker: SDZ.SW
- Home exchange: SIX Swiss Exchange
- Lang & Schwarz price: 88.11 euros on November 18, 2026, at 18:01 CET
Swiss market developments are available in the Current market reports.
